Latest:
Future Directions in Renal Cell Carcinoma
Panelists discuss emerging research directions and novel therapeutic combinations poised to shape the next generation of renal cell carcinoma management.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Elizabeth Whittington
Latest:
Long-term Aspirin Use Decreases Risk of GI Cancers, Especially Colorectal
A recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.
Ellyn Matthews, PhD
Latest:
Ellyn Matthews Addresses Misconceptions About Sleep Disturbances
Ellyn Matthews, PhD, RN, AOCNS, CBSM, who holds the Elizabeth Stanley Cooper Endowed Chair in Oncology Nursing at the University of Arkansas for Medical Sciences, addresses common misconceptions that patients with cancer have about sleep disturbances.
Emanuel F. Petricoin, III, PhD
Latest:
Chip Petricoin on the Discovery of New Biomarkers
Emanuel F. "Chip" Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the discovery of new biomarkers in breast cancer.
Emanuela Palmerini, MD
Latest:
Dr. Palmerini on Long-term Efficacy of Denosumab in Giant Cell Tumor of Bone
Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Rizzoli Orthopaedic Institute, discusses the long-term efficacy of denosumab (Xgeva) in patients with giant cell tumor of bone.
Emese Zsiros, MD, PhD
Latest:
Dr. Zsiros Discusses Pembrolizumab Triplet in Recurrent Ovarian Cancer
Emese Zsiros, MD, PhD, discusses the results of her recent phase II trial that set out to evaluate the use of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Emily A. Barber, BS
Latest:
Best Initial Treatment Strategies for EGFR-Mutant Lung Cancer
This review will focus on current therapies used in the first-line setting for advanced EGFR mutation positive non–small cell lung cancer (NSCLC) followed by emerging data that may lead to a transition in the choice for initial therapy in these patients.